drugset
drugset / Trial / NCT01977651

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

NCT01977651 ↗

Phase 4 Completed 424 enrolled Astellas Pharma Global Development, Inc. Medivation LLC, a wholly owned subsidiary of Pfizer Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for seizure.

Timeline

Start
2013-09-25
Primary completion
2016-02-01
Completion
2019-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg Oral

Indications

castration-resistant prostate carcinoma